Cargando…
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768112/ https://www.ncbi.nlm.nih.gov/pubmed/23787395 http://dx.doi.org/10.1038/leu.2013.190 |
| _version_ | 1782283740086534144 |
|---|---|
| author | Fink, A M Böttcher, S Ritgen, M Fischer, K Pflug, N Eichhorst, B Wendtner, C-M Winkler, D Bühler, A Zenz, T Staib, P Mayer, J Hensel, M Hopfinger, G Wenger, M Fingerle-Rowson, G Döhner, H Kneba, M Stilgenbauer, S Busch, R Hallek, M |
| author_facet | Fink, A M Böttcher, S Ritgen, M Fischer, K Pflug, N Eichhorst, B Wendtner, C-M Winkler, D Bühler, A Zenz, T Staib, P Mayer, J Hensel, M Hopfinger, G Wenger, M Fingerle-Rowson, G Döhner, H Kneba, M Stilgenbauer, S Busch, R Hallek, M |
| author_sort | Fink, A M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3768112 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-37681122013-09-11 Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab Fink, A M Böttcher, S Ritgen, M Fischer, K Pflug, N Eichhorst, B Wendtner, C-M Winkler, D Bühler, A Zenz, T Staib, P Mayer, J Hensel, M Hopfinger, G Wenger, M Fingerle-Rowson, G Döhner, H Kneba, M Stilgenbauer, S Busch, R Hallek, M Leukemia Letter to the Editor Nature Publishing Group 2013-09 2013-07-09 /pmc/articles/PMC3768112/ /pubmed/23787395 http://dx.doi.org/10.1038/leu.2013.190 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Letter to the Editor Fink, A M Böttcher, S Ritgen, M Fischer, K Pflug, N Eichhorst, B Wendtner, C-M Winkler, D Bühler, A Zenz, T Staib, P Mayer, J Hensel, M Hopfinger, G Wenger, M Fingerle-Rowson, G Döhner, H Kneba, M Stilgenbauer, S Busch, R Hallek, M Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| title | Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| title_full | Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| title_fullStr | Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| title_full_unstemmed | Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| title_short | Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| title_sort | prediction of poor outcome in cll patients following first-line treatment with fludarabine, cyclophosphamide and rituximab |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768112/ https://www.ncbi.nlm.nih.gov/pubmed/23787395 http://dx.doi.org/10.1038/leu.2013.190 |
| work_keys_str_mv | AT finkam predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT bottchers predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT ritgenm predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT fischerk predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT pflugn predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT eichhorstb predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT wendtnercm predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT winklerd predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT buhlera predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT zenzt predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT staibp predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT mayerj predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT henselm predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT hopfingerg predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT wengerm predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT fingerlerowsong predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT dohnerh predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT knebam predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT stilgenbauers predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT buschr predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab AT hallekm predictionofpooroutcomeincllpatientsfollowingfirstlinetreatmentwithfludarabinecyclophosphamideandrituximab |